Fc receptor blockade and immune thrombocytopenic purpura

doi:10.1016/S0037-1963(00)90104-5

Seminars in Hematology

Volume 37, Issue 3, July 2000, Pages 261-266

https://doi.org/10.1016/S0037-1963(00)90104-5 Get rights and content

Abstract

Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into normal recipients were demonstrated in 1965. Subsequently, the antibody-coated chromium-labeled red blood cell clearance study was developed to allow direct in vivo assessment of Fc receptor (FcR) blockade. This was first demonstrated for corticosteroids but more extensive investigation began with the study of intravenous infusions of gammaglobulin (IVIg). The unequivocal demonstration of FcR blockade following IVIg initiated novel approaches. One involved the infusion of a monoclonal anti-FcRIII ligand-blocking antibody into patients with refractory ITP. The efficacy of this treatment demonstrated that FcR blockade was not an epiphenomenon but rather an important mechanism of the increase in the platelet count in patients with ITP. Confirmation of its importance was obtained from the infusion of intravenous (IV) anti-D and the use of the isolated Fc piece of IgG. Recent studies have begun to explore the possibility of a monoclonal anti-FcRI and monoclonal anti-Ds. In summary, FcR blockade is an important mechanism of treatment effect in patients with ITP. Cytokine release as a consequence of this interaction and other immunomodulatory effects have only begun to be studied.

References (42)

P Berchtold et al.
Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin
Blood
(1989)
V Blanchette et al.
Randomized trial of immunoglobulin G, intravenous anti-D and oral prednisone in acute immune thrombocytopenic purpura
Lancet
(1994)
BJ Boughton
Anti-D IG for treatment of immune thrombo-cytopenic purpura
Blood
(1991)
JB Bussel et al.
Anti-D IG for treatment of immune thrombocytopenic purpura
Blood
(1991)
JB Bussel et al.
Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect
Blood
(1988)
JB Bussel et al.
Intravenous gammaglobulin treatment of chronic idiopathic thrombocy-topenic purpura
Blood
(1983)
M Debre et al.
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura
Lancet
(1993)
B Heyman
Complement and Fc-receptors in regulation of the antibody response
Immunol Lett
(1996)
P Imbach et al.
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
Lancet
(1981)
JG Kelton et al.
The concentration of IgG in the serum is a major determinant of Fc-dependent reticuloendothelial function
Blood
(1985)

BM Kumpel et al.

Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D⁺ red blood cells and suppression of Rh D immunization in Rh D-volunteers

Blood

(1995)

JV Ravetch

Fc receptors

Curr Opin Immunol

(1997)

A Salama et al.

Effect of intravenous immunoglobulin in immune thrombocytopenia

Lancet

(1983)

A Scaradavou et al.

Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients

Blood

(1997)

PA Tovo et al.

Fc-depleted vs. intact intravenous immunoglobulin in chronic ITP

J Pediatr

(1984)

T Becker et al.

Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D)

Eur J Pediatr

(1986)

P Boros et al.

Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients

J Immunol

(1993)

SEG Burdach et al.

Mechanisms of intravenous immunoglobulin treatment in childhood acute idiopathic thrombocytopenic purpura. Comparison of F(ab)2 versus Fc containing IgG

Pediatr Res

(1985)

JB Bussel et al.

Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenic and posttransfusion purpura

JB Bussel et al.

The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease

Br J Haematol

(1984)

JB Bussel et al.

Infusion of a monoclonal anti-FcR III in patients with refractory ITP

Neoadjuvant Chemother

(1990)

Cited by (96)

Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP
2023, Blood Advances
Immune thrombocytopenia (ITP) is the consequence of a complex, still incompletely understood immunological dysregulation. Proposed mechanisms include autoantibody-induced platelet destruction, impaired platelet production as well as abnormalities in T-cell immunity, such as T helper cells (Th1) polarization, a high proportion of Th17 cells, and a reduced number of regulatory T cells. Although the etiology of ITP is incompletely understood and considered multifactorial in most cases, genetic variants are thought to play a key role in susceptibility to ITP, especially in persistent or chronic ITP. Efforts are currently underway to uncover possible predisposing genetic factors for the development of ITP. Single-nucleotide polymorphisms and copy number variations have been identified in several immune-related genes, such as cytokine genes, Fcγ receptor genes or T-cell costimulation genes, and have been associated with patients’ susceptibility to ITP. However, because of the clinical heterogeneity and low incidence of ITP it remains challenging to perform genetic analyses with sufficiently large sample size within informative patient populations, highlighting the need for collection of well-annotated biomaterials in clinical trials or registry projects. Another significant challenge is to go beyond performing association studies alone and to establish genotype-phenotype associations, thus proving causality between a genetic alteration and ITP pathogenesis. This review summarizes our current knowledge on genetic alterations identified as potential predisposing factors for the development of ITP in adults, thereby addressing signaling pathways considered critical for ITP pathogenesis.
Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
2023, Biomedicine and Pharmacotherapy
The coronavirus disease 2019 (COVID-19) pandemic has become a huge obstacle to the health system due to the high rate of contagion. It is postulated that intravenous immunoglobulins (IVIG) can lower the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related inflammation and prevent the development of acute respiratory distress syndrome (ARDS). The main advantages of IVIG treatment might be targeting cytokine storm in severe and critical COVID-19 by influences on complement, innate immune cells, effector T-cells, and Tregs. Randomized clinical trials (RCTs) and non-RCTs evaluating the safety and efficacy of IVIG in patients with severe/critical COVID-19 were performed. It seems that early administration of high-dose IVIG (in the acceleration phase of the disease) in severe or especially critical COVID-19 may be an effective therapeutic option, but there are no strong data to use it routinely. The results regarding mortality reduction are inconclusive. Additionally, IVIG treatment carries a risk of complications that should be considered when initiating treatment. However, given the COVID-19 mortality rate and limited therapeutic options, the use of IVIG is worth considering. This review summarizes the development and highlights recent advances in treatment with IVIG of severe/critically ill COVID-19 patients.
C5aR2 Deficiency Ameliorates Inflammation in Murine Epidermolysis Bullosa Acquisita by Regulating Fcγ Receptor Expression on Neutrophils
2022, Journal of Investigative Dermatology
Citation Excerpt :
Excitingly, we found a second mechanism that accounts for blunted neutrophil activity in C5ar2–/– mice. Neutrophils from C5ar2–/– animals exhibited a strong decrease in the A/I ratio of FcγRs (Figure 4b, d, and e), which is known to suppress inflammation triggered by (auto-) antibodies (Bussel, 2000; Nimmerjahn and Ravetch, 2008). It has been previously proposed that there is critical bidirectional crosstalk between C5a and FcγR activation on cells expressing both receptor families, including neutrophils.
Epidermolysis bullosa acquisita (EBA) is a rare blistering skin disease induced by autoantibodies directed against type VII collagen. The transfer of antibodies against murine type VII collagen into mice mimics the effector phase of EBA and results in a subepidermal blistering phenotype. Activation of the complement system, and especially the C5a/C5aR1 axis driving neutrophil activation, is critical for EBA pathogenesis. However, the role of the alternative C5a receptor, C5aR2, which is commonly thought to be more immunosuppressive, in the pathogenesis of EBA is still elusive. Therefore, we sought to delineate the functional relevance of C5aR2 during the effector phase of EBA. Interestingly, C5ar2^–/– mice showed an attenuated disease phenotype, suggesting a pathogenic contribution of C5aR2 in disease progression. In vitro, C5ar2^–/– neutrophils exhibited significantly reduced intracellular calcium flux, ROS release, and migratory capacity when activated with immune complexes or exposed to C5a. These functions were completely absent when C5ar1^–/– neutrophils were activated. Moreover, C5aR2 deficiency lowered the ratio of activating and inhibitory FcγRs, impeding the sustainment of inflammation. Collectively, we show here a proinflammatory contribution of C5aR2 in the pathogenesis of antibody-induced tissue damage in experimental EBA.
An appraisal of antigen identification and IgG effector functions driving host immune responses in multiple sclerosis
2021, Multiple Sclerosis and Related Disorders
Increased immunoglobulin G (IgG) antibodies and oligoclonal bands (OCB) are the most characteristic features of multiple sclerosis (MS), a neuroinflammatory demyelinating disease with neurodegeneration at chronic stages. OCB are shown to be associated with disease activity and brain atrophy. Despite intensive research over the last several decades, the antigen specificities of the IgG in MS have remained elusive. We present evidence which supports that intrathecal IgG is not driven by antigen-stimulation, therefore provide reasoning for failed MS antigen identification. Further, the presence of co-deposition of IgG and activated complement products in MS lesions suggest that the IgG effector functions may play a critical role in disease pathogenesis.
IVMP1IVIG raises platelet counts faster than IVIG alone: Results of a randomized, blinded trial in childhood ITP
2020, Blood Advances
Children with immune thrombocytopenia (ITP) rarely suffer from life-threatening bleeds (eg, intracranial hemorrhage). In such settings, the combination of IV methylprednisolone (IVMP) with IV immune globulin (IVIG) is used to rapidly increase platelet counts (PCs). However, there are no controlled data to support using combination therapy over IVIG alone. We conducted a randomized, double-blind, placebo-controlled study to evaluate the rapidity of the PC increment and associated adverse events (AEs) between 2 regimens: A (IV placebo) and B (IVMP 30 mg/kg), both given over 1 hour, followed in both cases by IVIG (Gamunex 10%) 1 g/kg over 2-3 hours in children 1-17 years old with primary ITP and PCs <20 × 10⁹/L in whom physicians had decided to treat with IVIG. Thirty-two children (ages: median, 8 years; range, 1.2-17.5 years) with a mean baseline PC of 9.2 × 10⁹/L participated. Eighteen were randomized to regimen A and 14 to regimen B. By 8 hours after initiating therapy, 55% of all children had a PC ≥20 × 10⁹/L (no group difference). By 24 hours, mean PCs were 76.9 × 10⁹/L (B) vs 55 × 10⁹/L (A) (P = .06; P = .035 when adjusted for intergroup differences in patient ages). No patient experienced severe bleeding/unexpected severe AEs. There were statistically fewer IVIG-related headaches in the group receiving combination therapy (P = .046). Our findings show a rapid response to IVIG with/without steroids and provide evidence to support the use of IVMP+IVIG in life-threatening situations. This trial was registered at www.clinicaltrials.gov as #NCT00376077.
Immune thrombocytopenia (ITP)
2019, Platelets
Primary immune thrombocytopenia (ITP) is an autoimmune disease that results in often severe thrombocytopenia with a variable degree of bleeding symptoms. Fortunately, even at low platelet counts, serious hemorrhage is rare. Current management is largely based on estimation of the individual patient’s bleeding risk which includes consideration of platelet count, bleeding symptoms, comorbidities and medications, response to previous treatments, and multiple lifestyle variables including fatigue. This chapter comprehensively reviews the pathophysiology, diagnosis, and management of ITP, and describes areas under active investigation and future research needs.

View all citing articles on Scopus

View full text

Fc receptor blockade and immune thrombocytopenic purpura

Abstract

Blood

Lancet

Blood

Blood

Blood

Blood

Lancet

Immunol Lett

Lancet

Blood

Blood

Curr Opin Immunol

Lancet

Blood

J Pediatr

Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D)

Eur J Pediatr

Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients

J Immunol

Mechanisms of intravenous immunoglobulin treatment in childhood acute idiopathic thrombocytopenic purpura. Comparison of F(ab)2 versus Fc containing IgG

Pediatr Res

Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenic and posttransfusion purpura

The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease

Br J Haematol

Infusion of a monoclonal anti-FcR III in patients with refractory ITP

Neoadjuvant Chemother